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Background. Diabetic nephropathy (DN) is a common complication of diabetes mellitus (DM). We studied the expression of special AT-rich sequence binding protein 1 (SATB1) and phosphatase and tensin homologue (PTEN) in the kidneys of diabetic rats during ageing. Methods. Male Sprague Dawley rats were injected with 55 mg/kg streptozotocin (STZ) (DM group) or with citrate buffer (control group). Kidneys were collected after 2 weeks, 6 months and 12 months, and were analysed in three different kidney structures: glomeruli, proximal (PCT) and distal convoluted tubules (DCT). Sections were stained immunohistochemically, using SATB1 and PTEN. Results. Significant differences in marker expression were observed after 2 weeks, with higher SATB1 expression and lower PTEN expression in diabetic rats. PTEN was more highly expressed in controls after 6 and 12 months. After 12 months, there was higher SATB1 expression in diabetic rats. In the glomeruli, control rats had higher PTEN expression, whereas diabetic rats had higher SATB1 expression, after 12 months. PTEN expression increased from 2 weeks to 12 months in both the PCT and DCT of control rats. SATB1 was expressed exclusively in the PCT of diabetic rats after 2 weeks, and its expression in the DCT was higher in controls. After 6 months, both the PCT and DCT showed higher SATB1 expression in diabetic rats. Conclusions. The major changes in expression of SATB1 and PTEN occur after 2 weeks of DM onset, particularly in the PCT, implying an early onset of pathophysiological changes in diabetic kidneys, which would normally occur with ageing. These findings help to contribute to our understanding of changes associated with DN and guide towards possible appropriate treatment modalities.
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I N T R O D U C T I O N
The most prevalent cause of chronic kidney disease in developed countries is diabetic nephropathy (DN), which can lead to end-stage renal disease and premature death [1] . DN is mainly related to glomerular dysfunction [2] . Other associated features include thickening of the glomerular basement membrane and mesangial expansion, as well as podocyte foot process shortening, thinning and detachment [3] . Moreover, the fenestrated area of endothelial cells is reduced, the glycocalyx weakened, and the communication between glomerular endothelial cells and adjacent glomerular cells distorted [3] .
Specific factors can be used to study developmental pathways and kidney changes in diabetic rats. Special AT-rich sequence binding protein 1 (SATB1), a tissue-specific nuclear matrix-binding protein, is responsible for the regulation of chromatin structure formation and tissue-specific gene expression. In healthy cells and tissues, SATB1 is expressed at low levels [4, 5] . It is mainly expressed in T cells, where it plays a major role in T-cell development, as well as in early red blood cell differentiation, cell homeostasis and response to various stimuli [4, 6] . Studies have shown that SATB1 is abnormally expressed in different types of cancer [7, 8] , with its expression gradually increasing with cancer progression, which is crucial for tumour survival and metastasis [9, 10] . Mao et al. showed that the expression of SATB1 is involved in the progression and metastasis of prostate cancer [7] . Another study demonstrated overexpression of SATB1 in colorectal cancer tissues and cell lines [11] . However, in the current literature, there is no investigation of the role of SATB1 in renal tissue.
Phosphatase and tensin homologue (PTEN) is a major component of the phosphatidylinositol 3 (PI3) kinase/protein kinase B (PKB/AKT) signalling pathway, in which its function is to restrain the pathway [12] [13] [14] . By suppressing the activity of the PI3K/AKT pathway, PTEN acts as a tumour suppressor [12] . PTEN also plays a role in various cellular processes, such as survival, proliferation, energy metabolism and cellular structure maintenance, as well as inhibiting cellular migration [14, 15] . It is also known to initiate apoptotic pathways, as well as cell cycle arrest [16] . Decreased expression of PTEN has been reported in mesangial cells and podocytes in diabetic db/db mice and also in patients with DN [17] . The same was observed in renal tubular epithelial cells of diabetic rats, leading to overactivation of the PI3K-PKB/AKT pathway by transforming growth factor-beta 1 (TGF-b1), thus aiding in the initiation and progression of DN [18] . To our knowledge, there are no longterm studies that quantify the expression of SATB1 and PTEN in kidneys of diabetic rats during ageing.
M A T E R I A L S A N D M E T H O D S

Experimental animals
Male Sprague Dawley rats were provided by the animal husbandry of the University of Split School of Medicine. Rats weighed between 160 and 180 g and were reared under controlled conditions, which included a temperature of 22 6 1 C and a light schedule of 12 h of light and 12 h of dark.
Induction and validation of diabetes
Experiments were conducted using a type 1 diabetes mellitus (DM1) rat model. DM was induced by an intraperitoneal injection of 55 mg/kg streptozotocin (STZ) freshly dissolved in citrate buffer, pH 4.5, after fasting overnight. Rats were fed with normal laboratory chow ad libitum, made up of 27% proteins, 9% fat and 64% carbohydrates (4RF21 GLP, Mucedola, Settimo Milanese, Italy).
Plasma glucose levels and body weights were used to validate the induction of DM. Plasma glucose levels using tail vein blood was measured using a OneTouch Vita instrument (LifeScan, High Wycombe, UK). Rats were considered diabetic with a glucose level >16.5 mmol/L and were therefore included in further experiments. A weighing scale was used to measure their body weight.
Diabetic rats were allocated into three groups, based on the duration of diabetes from injection of STZ until the end of the experiment: 2 weeks (DM-2 w), 6 months (DM-6 m) and 12 months (DM-12 m). For each diabetic group, there was a matched control group, which was kept in the experiment for the same respective period (C-2 w, C-6 m, C-12 m). Control rats were injected intraperitoneally with citrate buffer only. In each diabetic and control group, there were six animals for each required age.
Tissue collection and immunohistochemistry
Rats were anaesthetized using isoflurane (Forane, Abbott Laboratories, Queenborough, UK). Next, the rats were perfused with 300 mL of Zamboni's fixative [4% paraformaldehyde and 15% picric acid in 0.1 M phosphate-buffered saline (PBS)], immediately after washing with saline, at pH 7.4. Kidney samples were removed for further analyses and post-fixed in the same fixative. Transverse cuts were made on the kidneys, and the tissue was embedded in paraffin blocks and cut into sections 7 mm thick. Following deparaffinization, the sections were rehydrated using ethanol and water, and then briefly rinsed with distilled water, SATB1 and PTEN expression in diabetic kidneys followed by heating in sodium citrate buffer (pH 6.0) at 95 C for 12 min in a microwave oven. After cooling to room temperature, the sections were incubated with primary antibodies.
Goat antiserum SATB1 (SC-5930, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) was diluted 1:200 and mouse antiserum PTEN (MAB847, R&D Systems, Minneapolis, MN, USA) was diluted 1:100, both in Dako REAL antibody diluent (Dako Denmark A/S, Glostrup, Denmark), and then applied to the sections. The primary antibodies were left overnight in a humidified chamber at room temperature. After rinsing the sections with PBS, they were incubated for 1 h in a humidified chamber with a combination of secondary antibodies: donkey anti-goat immunoglobulin G Heavy and Light chains (IgG H&L) (Alexa Fluor V R 488) (ab150129, manufacturer, city, US state if applicable, country) and goat anti-mouse IgG H&L [Tetramethylrhodamine (TRITC)] (ab6786, Abcam, London, UK).
Sections were then rinsed with PBS and then stained with 4 0 ,6-Diamidine-2 0 -phenylindole dihydrochloride (DAPI). DAPI stains nuclear specifically and is used in multicolour fluorescent techniques. Stained kidney sections were viewed and photographed, using a BX51 microscope (Olympus, Tokyo, Japan) equipped with a DP71 digital camera (Olympus), and processed with Cell A Imaging Software for Life Sciences Microscopy (Olympus).
Kidney sections were analysed within three structures: glomeruli, proximal (PCT) and distal convoluted tubules (DCT) (Figure 1 ). In each of the listed sections, the Â40 objective was used to capture 10 non-overlapping fields for further analysis. Each field constituted one image. Microphotographs were analysed, using ImageJ software (National Institutes of Health, Bethesda, MD, USA), by counting the number of positive cells, which was determined by the colour staining intensity (green for SATB1 and red for PTEN) in the kidney tissue ( Figure 2 ). The number of positive cells in the three kidney structures (glomeruli, PCT and DCT) was compared between the control and diabetic groups. After separate analyses were conducted for the different kidney structures for each group and period, data were pooled for all kidney structures of control or diabetic rats, and re-analysed.
Statistics
For statistical analysis, a chi-squared test was used to examine differences between groups after testing the data distribution. Data were expressed as the mean 6 standard deviation. Statistical significance was set at P < 0.05. 
Ethics
The experimental protocol was approved by the Ethics Committee of the University of Split School of Medicine.
R E S U L T S
Total number of SATB1-and PTEN-positive cells in groups of diabetic and control rat kidneys
We first analysed the total number of positive cells between the groups, including all three structures of the kidney cortex (glomeruli, PCT and DCT). In the control groups (C-2 w, C-6 m, C-12 m), SATB1 expression increased with time (P < 0.0001) (Figure 3a ). There was a significant difference in the total number of SATB1-positive cells among the three diabetes groups (DM-2 w, DM-6 m, DM-12 m) (P < 0.0001) (Figure 3a) . There was no significant difference in the total number of SATB1-positive cells in the DM-2 w group, compared with the DM-6 m group (P ¼ 0.4431) (Figure 3a) . A significant difference was observed between the DM-2 w and DM-12 m groups, with more positive cells in the DM-12 m group (P < 0.0001). A greater proportion of SATB1-positive cells were also observed in DM-12 m rats, compared with the DM-6 m group (P < 0.0001) (Figure 3a ). In addition, there was SATB1 and PTEN expression in diabetic kidneys a significant difference in the total number of SATB1-positive cells between the control and diabetes groups 2 weeks post-DM induction (C-2 w and DM-2 w) (P < 0.0001), with more positive cells in DM-2 w rats (Figure 3a) . There was no significant difference in the number of SATB1-positive cells between the control and diabetes groups 6 months after post-DM induction (P ¼ 0.2644). A significant difference was observed between the control and diabetes groups 12 months post-induction (P < 0.001) in favour of the diabetes group, which had more positive cells (Figure 3a) .
In control groups (C-2 w, C-6 m, C-12 m), the highest number of PTEN-positive cells was observed 12 months after induction (P < 0.0001) (Figure 3b) . Similar results were obtained in the diabetes groups (P < 0.0001) (Figure 3b) . On comparing the C-2 w and DM-2 w groups, there was a significant difference in the total number of PTEN-positive cells (P < 0.01), with more positive cells in control animals (Figure 3b ). A similar difference was observed when comparing the C-6 m and DM-6 m groups (P < 0.0001) (Figure 3b) . A significant difference in the number of PTEN-positive cells between the control and diabetes groups was seen 12 months after induction (P < 0.0001), also in favour of control animals (Figure 3b ).
SATB1-and PTEN-positive cells in different kidney structures in diabetic and control rats
Two weeks after DM induction, there was complete absence of SATB1-and PTEN-positive cells in the glomeruli of diabetic and control rats (Figure 4 ). In the PCT, SATB1-positive cells were present in diabetic animals only (Figure 4a ) and PTENpositive cells were found in control rats (P < 0.0001) (Figure 4b ). In the DCT, control groups had higher numbers of both SATB1-and PTEN-positive cells (P < 0.0001) (Figure 4b and B) .
Six months post-induction, SATB1-positive cells were present in the glomeruli of control rats only (Figure 5a) . In both the PCT and DCT, a significant increase in the number of SATB1-positive cells was observed in the diabetes group, compared with the control group (P < 0.001) (Figure 5a ). PTEN expression in the controls was higher, compared with diabetic and diabetes (DM) groups. Data presented as mean 6 SD, chisquared test. Asterisks denote significant difference. *P < 0.05, **P < 0.01, ***P < 0.001. rats, in all kidney structures examined (P < 0.0001) (Figure 5b ). Twelve months post-induction, a significant increase in the number of SATB1-positive cells was observed in the glomeruli of diabetic rats (P < 0.0001) (Figure 6a ), whereas the number of PTEN-positive cells was significantly higher in controls (P < 0.01) (Figure 6b ). In the PCT and DCT, higher numbers of PTEN-positive cells were observed in control animals (P < 0.0001), whereas there was no significant difference in SATB1-positive cells between controls and diabetic rats ( Figure 6 ).
Semi-quantification of SATB1 and PTEN staining intensity in kidneys
The DM-2 w and DM-6 m groups showed strong SATB1 expression in both the PCT and DCT, but not the glomeruli, whereas in the C-2 w group, there was strong granular expression of SATB1 in the DCT only. In the C-6 m group, there was mild granular expression of SATB1 throughout the kidney. SATB1 expression in both the C-12 m and DM-12 m groups was mild, with occasional granular expression of SATB1 in the DCT in the DM-12 m group, especially in the macula densa.
In both C-2 w and DM-2 w animals, there was strong PTEN expression in the PCT and DCT, but not the glomeruli, whereas the parietal layer of the Bowman's capsules had mildly positive staining in both groups. The C-6 m group had strong expression of PTEN in all kidney structures, with positive PTEN staining in healthy glomeruli being most apparent in podocytes and blood vessels, both within the glomeruli and interstitium. In the DM-6 m group, mild expression of PTEN was observed in all structures, and glomeruli typically were found to demonstrate more pronounced glomerular sclerosis. The C-12 m group showed a similar PTEN staining pattern to the C-6 m group. In the DM-12 m group, mild expression of PTEN was seen in all kidney structures, with strong PTEN expression observed in blood vessels and interstitial cells.
D I S C U S S I O N
In this study, changes in SATB1 and PTEN expression in kidneys of diabetic and control rats from different age groups were Data presented as mean 6 SD, chi-squared test. Asterisks denote significant difference: **P < 0.01, ***P < 0.001. analysed. This is the first long-term study that quantified the expression of these two markers in diabetic and control kidneys during ageing. In healthy cells and tissues responsible for the regulation of chromatin structure formation and tissue-specific gene expression, SATB1 is expressed at low levels [4, 5] . In our study, SATB1 expression almost doubled 2 weeks post-DM induction in the diabetes group, compared with controls. This is an important finding because it indicates that kidney damage is already present 2 weeks after the onset of DM, with subsequent worsening as occurs with ageing. This could represent the loss of compensatory mechanism of the kidneys due to kidney damage. At 6 months post-DM induction, SATB1 expression was very high, with no difference between the diabetes and control groups, but after 12 months, a higher expression of SATB1 was observed again in diabetic rats, compared with controls.
Significant differences in SATB1 expression were found when comparing different kidney structures. The most interesting finding was an extremely high expression of SATB1 in the PCT 2 weeks post-induction in the diabetes group, with complete absence of SATB1 in the PCT of control animals. With time, although SATB1 expression in the PCT was high in both groups, it still remained higher in diabetic animals at 6 months post-induction and equally high after 12 months. On the other hand, there was no SATB1 expression in the glomeruli at 2 weeks post-induction in either groups. Interestingly, at 6 months post-induction, SATB1 expression in the glomeruli was seen in control animals, but not in the diabetes group, whereas after 12 months, SATB1 expression was higher in diabetic animals. These findings imply that the most significant pathological changes in the PCT occur 2 weeks after DM onset, with impaired reasorption being evident, whereas glomeruli seem to remain intact. This implies that glomerular changes associated with DM or ageing occur later (in the case of control animals after 6 months from DM induction), with the highest SATB1 expression at 12 months post-induction, particularly in diabetic animals. These findings coincide with results from semi-quantification analyses showing strong SATB1-positive expression in damaged sclerotic glomeruli after 12 months of DM.
On comparing both markers in animals within the same groups, SATB1 was more highly expressed in diabetic rats, whereas PTEN was more highly expressed in control animals. Studies have reported that b-cell deletion of PTEN in mouse models leads to a considerable increase in total islet mass of the injured pancreas [19] . Decreased expression of PTEN has been reported in mesangial cells and podocytes in diabetic db/db mice and also in patients with DN [17] . Similar findings were observed in renal tubular epithelial cells in diabetic rats, whereby TGF-b1 contributed to the initiation and progression of DN by overactivation of the PI3K-PKB/AKT pathway [18] . It has been reported that tubular and interstitial PTEN expression was dramatically decreased in several models of renal injury, with PTEN expression loss initiating tubular dysfunction [20] . In this study, we also observed a decrease in PTEN expression in diabetic rats 12 months after DM induction, compared with controls, and significant differences were observed in different kidney structures, namely the glomeruli, PCT and DCT. PTEN expression was decreased in diabetic rats at all three time points. PTEN downregulation mediates renal extracellular matrix production through activation of Act, and its upregulation has been suggested to be a potential way to mitigate the development of renal fibrosis in chronic renal disease [21] . Wang et al. sacrificed rats after 12 weeks and found that PTEN expression was significantly reduced in the diabetes group [18] . Lin et al. studied mouse models of DM where PTEN expression was decreased in mesangial cells, contributing to the expansion of the mesangial matrix, but how PTEN in podocytes influences the development of DN remains unknown [17] . They also found that deletion of insulin receptors from podocytes decreased insulin receptor substrate 1 (IRS1)-associated PI3K activity, which was followed by podocyte apoptosis and glomerulosclerosis [17] . Zhu et al. reported that PTEN regulates renal extracellular matrix deposition via increased connective tissue growth factor (CTGF) in DM [21] .
Cellular changes occurring in DN have been investigated, but many remain poorly understood. Wu et al. showed that, in rats sacrificed after 1, 4 and 8 weeks, the autophagic disorder can contribute to early DN and that autophagy is important for regulation of cellular homeostasis in kidneys [22] . Menini et al. showed that there was a higher rate of glomerular cell apoptosis in diabetic rats, compared with controls, after 4 and 6 months, although no 12-month data were available [23] . They concluded that glomerular cell apoptosis, as the last feature, is preceded by glomerular and podocyte hypertrophy, podocytopathy and proteinuria, which can lead to mesangial expansion and glomerular sclerosis [23] . Similar findings were reported in other studies of rats sacrificed after 4 weeks, 8 weeks and 6 months, which showed glomerular apoptosis after 6 months of DM induction through E3 ubiquitin-protein ligase MIB-5 positivity, which can lead to glomerular sclerosis [24] . These results are in agreement with our observations of PTEN and SATB1 expression in these kidney structures.
Expression of SATB1 and PTEN has also been associated with tumourigenesis. In contrast to SATB1, PTEN has a protective role against tumourigenesis by dampening the activity of the PI3K/AKT signalling pathway [12] . The role of the PI3K/AKT pathway is to respond to mitogenic stimuli, activating an intracellular phosphorylation cascade, which leads to cellular proliferation and increased survival. So by limiting the activity of the pathway, PTEN acts as a tumour suppressor [12, 14] . Furthermore, PTEN is known to initiate apoptotic pathways, as well as cell cycle arrest [16] . Studies have shown that the loss of PTEN is evident in various types of tumours, such as breast and brain tumours, while an inherited loss of PTEN is seen in Cowden syndrome, a condition characterized by hyperproliferative benign and malignant tumours [14, 25] .
In conclusion, our results showed that the most significant changes in expression of both SATB1 and PTEN occur 2 weeks after the onset of DM, especially in PCTs, implying an early onset of pathophysiological changes in diabetic kidneys, which would normally occur with ageing. These findings indicate that DN originates in the PCT, in contrast to the previous belief that podocytes exhibiting functional impairment are the initial site of damage, and PCT dysfunction leads to glomerular filtration membrane damage and microalbuminuria [26] . Therefore, various markers that influence PCT function are important in the design of new treatment modalities. On comparing aged diabetic and control animals, more marked changes in marker expression are seen in diabetic animals, indicating more severe kidney damage as a result of disease. Further studies to examine changes occurring in the kidney during ageing will allow insights into the physiology of healthy and diabetic kidneys and help to elucidate the mechanisms underlying these changes.
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